Drug Profile
AK 123
Alternative Names: AK123Latest Information Update: 10 Aug 2020
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Aug 2020 Preclinical trials in Cancer in China (unspecified route)
- 21 Mar 2018 AK 123 is available for licensing as of 21 Mar 2018. http://www.akesobio.com
- 21 Mar 2018 Early research in Cancer in China (unspecified route) (Akeso Biopharma pipeline, March 2018)